cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Talaris Therapeutics Inc
1 own
1 watching
Current Price
$2.78
$0.11
(4.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
115.73M
52-Week High
52-Week High
9.21
52-Week Low
52-Week Low
0.89
Average Volume
Average Volume
0.23M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization115.73M
icon52-Week High9.21
icon52-Week Low0.89
iconAverage Volume0.23M
iconDividend Yield--
iconP/E Ratio--
What does the Talaris Therapeutics Inc do?
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Read More
How much money does Talaris Therapeutics Inc make?
News & Events about Talaris Therapeutics Inc.
Zolmax
7 months ago
HC Wainwright assumed coverage on shares of Talaris Therapeutics (NASDAQ:TALS Get Rating) in a report issued on Thursday, MarketBeat.com reports. The brokerage issued a buy rating and a $18.00 target price on the stock. Other equities analysts have also recently issued reports about the company. ...
Globe Newswire
1 year ago
Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients Initiated Phase 2 (FREEDOM-2) clinical trial for FCR001 in delayed tolerance induction patients BOSTON and LOUISVILLE, Ky., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ...
Benzinga
1 year ago
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. read more...
Frequently Asked Questions
Frequently Asked Questions
What is Talaris Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Talaris Therapeutics Inc shares?
plus_minus_icon
How can I buy Talaris Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Talaris Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Talaris Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Talaris Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Talaris Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Talaris Therapeutics Inc?
plus_minus_icon
What percentage is Talaris Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Talaris Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.78
$0.11
(4.12%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00